Drug intelligence / Profile preview

clindamycin + nicotinamide

Development stage: Unknown
Lead developer: Ardent Life Sciences
Modality: Small Molecules
Administration: Topical

Overview

Clinset-N is a topical combination therapy marketed by Ardent Life Sciences for the treatment of acne vulgaris. It contains clindamycin phosphate, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and nicotinamide (niacinamide), a form of vitamin B3 with potent anti-inflammatory properties. Clindamycin targets *Cutibacterium acnes*, the primary bacterium associated with acne, while nicotinamide helps reduce redness, swelling, and sebum production. This combination is designed to address both the bacterial and inflammatory components of acne.

Brand names: Clinset-N
Other names: clindamycin phosphate + niacinamide

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on clindamycin + nicotinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clindamycin + nicotinamide.

Explore the full profile